Neos Therapeutics, Inc. Form 8-K December 20, 2016

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 20, 2016

# NEOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction of incorporation)

001-37508 (Commission File Number) 27-0395455 (I.R.S. Employer Identification No.)

**2940 N. Highway 360, Grand Prairie, TX** (Address of principal executive offices)

**75050** (Zip Code)

Registrant s telephone number, including area code: (972) 408-1300

### Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On December 20, 2016, Neos Therapeutics, Inc. issued a press release entitled Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD (the Press Release). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit
No. Description

99.1 Press release dated December 20, 2016

2

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 20, 2016 NEOS THERAPEUTICS, INC.

By: /s/ Vipin Garg

Vipin Garg President and Chief Executive Officer

3

## EXHIBIT INDEX

Exhibit No. 99.1 Description

Press release dated December 20, 2016

4